Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Simendan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B known ✓ | Q13370 | 16/20 | 1.00 |
| ▸ | PDE3A known ✓ | Q14432 | 16/20 | 1.00 |
| ▸ | TNNC1 known ✓ | P63316 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 2/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levosimendan SCHEMBL1818300 | 1.00 | PDE3B (1.00) | PDE3BPDE3ATNNC1KDM4EALDH1A1 | |
| Levosimendan SCHEMBL83243 | 1.00 | PDE3B (1.00) | PDE3BPDE3ATNNC1KDM4EALDH1A1 | |
| Levosimendan SCHEMBL7417215 | 1.00 | PDE3B (1.00) | PDE3BPDE3ATNNC1KDM4EALDH1A1 | |
| Levosimendan SCHEMBL30307096 | 0.99 | PDE3B (0.98) | PDE3BPDE3ATNNC1KDM4EALDH1A1 | |
| Levosimendan SCHEMBL27742947 | 0.99 | PDE3B (0.98) | PDE3BPDE3ATNNC1KDM4EALDH1A1 | |
| Levosimendan SCHEMBL4737565 | 0.96 | PDE3B (0.91) | PDE3BPDE3ATNNC1KDM4EALDH1A1 | |
| Simendan SCHEMBL23630217 | 0.94 | PDE3B (0.88) | PDE3BPDE3ATNNC1KDM4EALDH1A1 | |
| Levosimendan SCHEMBL29197894 | 0.90 | PDE3B (0.81) | PDE3BPDE3ATNNC1KDM4EALDH1A1 | |
| SCHEMBL11946689 | 0.89 | PDE3B (0.80) | PDE3BPDE3ATNNC1KDM4EALDH1A1 | |
| SCHEMBL8320982 | 0.87 | PDE3B (0.77) | PDE3BPDE3ATNNC1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 588 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119307600-A | SNP locus related to simendan blood group and detection preparation | 青岛市中心血站(青岛市输血医学研究所) | 2025-01-14 | — | — | CN | claimed |
| CN-118638907-A | SNP marker for detecting easy-to-miss detection type Menbout phenotype | 中国人民解放军联勤保障部队第九六〇医院 | 2024-09-13 | — | — | CN | claimed |
| CN-116411059-B | SNP locus of simendan-like phenotype for initiating hemolytic transfusion reaction, application and reagent | 浙江省血液中心 | 2024-09-10 | — | — | CN | claimed |
| CN-118599982-A | SNP molecular marker and application thereof in detection of easy-to-miss detection type Menbout phenotype blood type | 中国人民解放军联勤保障部队第九六〇医院 | 2024-09-06 | — | — | CN | claimed |
| CN-113667673-B | Montellike FUT1236delG allele and detection method and application thereof | 武汉血液中心 | 2024-02-06 | — | — | CN | claimed |
| CN-116287321-B | SNP site of H blood group system antigen deletion related to immune hemolytic transfusion reaction, application and reagent | 浙江省血液中心 | 2023-11-24 | — | — | CN | claimed |
| CN-116411059-A | SNP locus of simendan-like phenotype for initiating hemolytic transfusion reaction, application and reagent | 浙江省血液中心 | 2023-07-11 | — | — | CN | claimed |
| CN-116287321-A | SNP site of H blood group system antigen deletion related to immune hemolytic transfusion reaction, application and reagent | 浙江省血液中心 | 2023-06-23 | — | — | CN | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| CN-105784895-B | A kind of method that impurity in Levosimendan is detected with high performance liquid chromatograph | 成都欣捷高新技术开发有限公司 | 2018-05-22 | — | — | CN | claimed |
| WO-1997035841-A2 | METHOD FOR OBTAINING PURE ENANTIOMERS OF A PYRIDAZINONE DERIVATIVE | Orion-Yhtymä Oy (FI) | 1997-10-02 | — | — | WO | claimed |
| US-5569657-A | TREATING CONGESTIVE HEART FAILURE | ORION-YHTYMA OY (FI) | 1996-10-29 | — | — | US | claimed |
| US-5512572-A | USING ((4-(1,4,5,6-TETRAHYDRO-4-METHYL-6-OXO-3-PYRIDAZINYL)-PHENYL) HYDRAZONO)PROPANEDINITRILE | ORION-YHTYMA OY (FI) | 1996-04-30 | — | — | US | claimed |
| EP-0383449-B1 | Pyridazinone derivatives and processes for preparing the same | ORION YHTYMAE OY (FI) | 1995-09-06 | — | — | EP | claimed |
| EP-0565546-B1 | (-)-[[4-(1,4,5,6-TETRAHYDRO-4-METHYL-6-OXO-3-PYRIDAZINYL)PHENYL]-HYDRAZONO]PROPANEDINITRILE | ORION YHTYMAE OY (FI) | 1995-03-08 | — | — | EP | claimed |
| EP-0639074-A1 | ANTI-ISCHEMIC MEDICAMENT | ORION-YHTYMÄ OY (FI) | 1995-02-22 | — | — | EP | claimed |
| WO-1993021921-A1 | ANTI-ISCHEMIC MEDICAMENT | Orion-Yhtymä Oy (FI) | 1993-11-11 | — | — | WO | claimed |
| WO-1992012135-A1 | (-)-[[4-(1,4,5,6-TETRAHYDRO-4-METHYL-6-OXO-3-PYRIDAZINYL)PHENYL]-HYDRAZONO]PROPANEDINITRILE | Orion-Yhtymä Oy (FI) | 1992-07-23 | — | — | WO | claimed |
| US-5019575-A | Congestive Heart Failure Treatment | ORION-YHTYMA OY (FI) | 1991-05-28 | — | — | US | claimed |
| EP-0383449-A2 | Pyridazinone derivatives and processes for preparing the same | ORION-YHTYMÀ OY (FI) | 1990-08-22 | — | — | EP | claimed |